PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 23, 2026Journal of Crohn s and Colitis

P0978SKYLINE-UC: The First Platform Study in Ulcerative Colitis Assessing Efficacy and Safety of Three Long-Acting Antibodies Administered as Single Agents and in Combinations

View Full Paper
Ask AI
Bookmark
Share

Authors

SDS DaneseVJV JairathJLJ Lu

Discussion

Loading...

Member takes

Overview

Platform study assesses efficacy and safety of long-acting antibodies in ulcerative colitis, indicating potential for innovative combinations.

Key Points

  • To evaluate the efficacy and safety of three long-acting monoclonal antibodies as single agents and in combinations for ulcerative colitis treatment.
  • Ongoing platform study with a master protocol for operational efficiency.
  • Includes an open-label Part A and randomized placebo-controlled Part B.
  • Part A assesses single-agent efficacy and safety; Part B explores single agents and combination therapies.
  • Predicted to reduce sample size by 45% compared to separate studies.
  • Preliminary efficacy and safety data expected in 2026 for Part A and 2027 for Part B.

Cite This Study

Danese et al. (2026) studied this question.

synapsesocial.com/papers/69731005c8125b09b0d1fb7fhttps://doi.org/10.1093/ecco-jcc/jjaf231.1159
View Full Paper
Ask AI
Bookmark
Share